Interim report January–June 2026: Strong license revenue and improved profitability

Second quarter 2026 (April–June)

• Net sales amounted to SEK 254.5 (209.2) million, an increase of 22 percent compared with the corresponding period in the preceding year. Calculated in local currencies, sales increased by 25 percent.
• License revenue amounted to SEK 84.8 (58.9) million and accounted for 33 (28) percent of net sales. The revenue loss for 2026 is assessed to be less than the range of SEK 60–90 million indicated after the cancellation by Intuitive of the previous Memorandum of Understanding.
• The gross margin was 69 (65) percent.
• Operating profit amounted to SEK 32.7 (-22.4) million.
• Net profit amounted to SEK 20.8 (-20.1) million, corresponding to earnings per share of SEK 0.41 (-0.39).
• Cash flow from operating activities amounted to SEK 15.3 (16.2) million. As at June 30, 2026, cash and cash equivalents amounted to SEK 658.4 (610.2) million.

First half of 2026 (January – June)

• Net sales amounted to SEK 490.0 (459.8) million, an increase of 7 percent compared with the corresponding period in the preceding year. Calculated in local currencies, sales increased by 11 percent.
• License revenue amounted to SEK 152.4 (142.7) million and accounted for 31 (31) percent of net sales.
• The gross margin was 68 (67) percent.
• Operating profit amounted to SEK 55.6 (1.5) million.
• Net profit amounted to SEK 39.5 (13.2) million, corresponding to earnings per share of SEK 0.77 (0.26).
• Cash flow from operating activities amounted to SEK 80.6 (11.3) million.

Gothenburg, Sweden, August 19, 2026
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/investor-relations/#press-releases
https://surgicalscience.com/aktien/financial-report

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.